Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.

Namour, Florence; Diderichsen, Paul Matthias; Cox, Eugène; Vayssière, Béatrice; Van der Aa, Annegret; Tasset, Chantal; Van't Klooster, Gerben

Namour, Florence; Diderichsen, Paul Matthias; Cox, Eugène; Vayssière, Béatrice; Van der Aa, Annegret; Tasset, Chantal; Van't Klooster, Gerben.

Affiliation

Namour F; Galapagos SASU, 102 Avenue Gaston Roussel, 93230, Romainville, France, florence.namour@glpg.com.

Clin Pharmacokinet ; 54(8): 859-74, 2015 Aug.

Article in En | MEDLINE | ID: mdl-25681059

Subject(s)

Antirheumatic Agents/administration & dosage; Antirheumatic Agents/pharmacokinetics; Arthritis, Rheumatoid/drug therapy; Arthritis, Rheumatoid/metabolism; Pyridines/administration & dosage; Pyridines/pharmacokinetics; Triazoles/administration & dosage; Triazoles/pharmacokinetics; Adult; Arthritis, Rheumatoid/blood; Dose-Response Relationship, Drug; Double-Blind Method; Healthy Volunteers; Humans; Janus Kinase 1/antagonists & inhibitors; Janus Kinase 1/metabolism; Male; Middle Aged; Phosphorylation/drug effects; Pyridines/blood; Triazoles/blood

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Pyridines / Triazoles / Antirheumatic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Humans / Male / Middle aged Language: En Journal: Clin Pharmacokinet Year: 2015 Document type: Article Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google